Български
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Comparison of Myoinositol and Metformin in PCO

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
Линкът е запазен в клипборда
СъстояниеВсе още не набира
Спонсори
Rashid Latif Medical College

Ключови думи

Резюме

Aim of the study is to compare the effect of myoinositol and metformin in the resumption of the spontaneous menstrual cycle in patients diagnosed with PCOS or having oligo/amenorrhea, reduction in weight and BMI, Improvement in the biochemical and clinical profile of patients with the polycystic syndrome.
The secondary outcome measured will be the rate of pregnancy, miscarriage and term pregnancy among these patients inducted in the study.
It will be a Three-arm prospective double-blind study. this clinical trial will be registered in Public registry. this RCT will be based on CONSORT statement. The patient coming to Gynecology OPD will be randomized into 3 groups GROUP A ( metformin 500 mg TDS), GROUP B( myoinositol 2mg x BD ), GROUP C.(both metformin,& myoinositol).each group will take folic acid and will be asked for lifestyle modifications.

Описание

PCOS is a common endocrine disorder in women of reproductive age associated with insulin resistance. Metformin and Myo-inositol being insulin sensitizers improve biochemical parameters. it is aimed to compare the effect of myoinositol and metformin in the resumption of the spontaneous menstrual cycle in patients diagnosed with PCOS or having oligo/amenorrhea, reduction in weight and BMI, Improvement in the biochemical and clinical profile of patients with the polycystic syndrome.

Inclusion criteria: will be based on the Rotterdam criteria of diagnosing PCO. Patients presenting with a history of secondary amenorrhea, irregular menstrual cycle, oligomenorrhea, weight gain, hirsutism, and already diagnosed cases of PCO will be included in this group.

Patients with history of Hyperprolactinemia, Cushing's disease, Hypothyroidism/ Hyperthyroidism, Pregnancy and nursing, Established type 1 or type 2 diabetes mellitus, Any history of drug intake e.g. anti-diabetic or estrogen and progesterone, History of treatment for the same complaint taken in the last 3 months, Unable to come for regular follow-ups, Any pathological cause of bleeding e.g. Fibroid, Polyp, Cervical pathology and known allergic to these drugs would be excluded.

Дати

Последна проверка: 11/30/2019
Първо изпратено: 10/21/2019
Очаквано записване подадено: 12/16/2019
Първо публикувано: 12/17/2019
Изпратена последна актуализация: 12/16/2019
Последна актуализация публикувана: 12/18/2019
Действителна начална дата на проучването: 12/31/2019
Приблизителна дата на първично завършване: 12/30/2020
Очаквана дата на завършване на проучването: 02/24/2021

Състояние или заболяване

PCOS

Интервенция / лечение

Drug: Metformin Hydrochloride

Drug: Myo-inositol

Фаза

-

Групи за ръце

ArmИнтервенция / лечение
Experimental: GROUP A ( metformin 500 mg TDS)
Life style modifications, Weight reduction and folic acid will be prescribed with metformin 500 mg three times a day
Experimental: GROUP B( myoinositol 2000mg x BD )
Life style modifications, Weight reduction and folic acid will be prescribed with myoinositol 2000 mg two times a day
Experimental: GROUP C.(both metformin,& myoinositol)
Life style modifications, Weight reduction and folic acid will be prescribed with both metformin,& myoinositol three and two times a day respectively

Критерии за допустимост

Възрасти, отговарящи на условията за проучване 16 Years Да се 16 Years
Полове, допустими за проучванеFemale
Приема здрави доброволциДа
Критерии

Inclusion Criteria:

It will be based on the Rotterdam criteria of diagnosing PCO. Patients presenting with a history of secondary amenorrhea, irregular menstrual cycle, oligomenorrhea, weight gain, hirsutism, and already diagnosed cases of PCO will be included in this group.

Exclusion Criteria:

- Hyperprolactinemia

- Cushing's disease

- Hypothyroidism/ Hyperthyroidism

- Pregnancy and nursing

- Established type 1 or type 2 diabetes mellitus

- Any history of drug intake e.g. anti-diabetic or estrogen and progesterone

- History of treatment for the same complaint taken in the last 3 months

- Unable to come for regular follow-ups

- Any pathological cause of bleeding e.g. Fibroid, Polyp, Cervical pathology

- Known allergic to these drugs

Резултат

Първични изходни мерки

1. Menstrual cycle regulation [Follow up at 3rd and 6th months]

In the resumption of the spontaneous menstrual cycle in patients diagnosed with PCOS or having oligo/amenorrhea.Improvement in the biochemical and clinical profile of patients with the polycystic syndrome

2. change in weight [Follow up at 3rd and 6th months]

change in weight and BMI. Weight in Kg(s) and height will be measured in meter(s). BMI will be calculated by dividing weight in Kg with height in meter square

Вторични изходни мерки

1. Pregnancy / Miscarriage [1 year]

The secondary outcome measured will be the rate of conception/pregnancy, miscarriage and term pregnancy among these patients inducted in the study.

Присъединете се към нашата
страница във facebook

Най-пълната база данни за лечебни билки, подкрепена от науката

  • Работи на 55 езика
  • Билкови лекове, подкрепени от науката
  • Разпознаване на билки по изображение
  • Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
  • Прочетете научни публикации, свързани с вашето търсене
  • Търсете лечебни билки по техните ефекти
  • Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите

Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания

Google Play badgeApp Store badge